Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts. Show more
101 Main Street, Cambridge, MA, 02142, United States
Market Cap
1.171B
52 Wk Range
$23.00 - $36.61
Previous Close
$25.08
Open
$24.89
Volume
184,433
Day Range
$23.81 - $25.74
Enterprise Value
1.011B
Cash
163.5M
Avg Qtr Burn
-21.58M
Insider Ownership
10.78%
Institutional Own.
59.91%
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Sutacimig (HMB-001) Details Glanzmann thrombasthenia | Phase 3 Initiation | |
Sutacimig (HMB-001) Details Congenital Factor VII deficiency | Phase 2 Data readout | |
HMB-002 Details Von Willebrand disease (VWD) | Phase 1/2 Data readout |
